TriStar Wellness Solutions® subsidiary HemCon Medical Technologies, a developer and marketer of advanced medical products, reports significant sales growth and momentum for the HemCon hemostatic product line in Japan, with 2014 first-quarter sales exceeding overall sales for the previous year.
The company attributes the growth to a new focus on sales and marketing efforts of HemCon’s exclusive partner in Japan, Zeria Pharmaceuticals Ltd. Co. (Zeria), who has worked with the HemCon product line since 2010. This collaboration ensures that current and newly developed products become the standard of care for hemostasis in the country.
HemCon products and solutions are designed to meet Japanese healthcare needs with particular focus on cardiac catheterization, emergency care, wound care, hemodialysis, and oral surgery. The company’s products provide bleeding control via its proprietary raw material formulation of chitosan. The company believes that the combination of its products with specific market intelligence and know-how from Zeria is the pathway to improving medical device innovation and supporting exciting new product introductions planned for the upcoming year.
“We are encouraged by the success we have seen in this first quarter,” William Perrin, HemCon’s Japan representative stated in the news release. “We are well positioned to continue with a strong sales effort and expect 2014 to be a very momentous year, which puts us in an excellent position to increase the HemCon product offerings in Japan.”
For more information visit www.hemcon.com or www.tstarwellness.com
Let us hear your thoughts below: